Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors
复制标题
DOI：
10.1158/1078-0432.ccr-07-0332
复制
发表时间：
2007-08-01
影响因子：
11.5
通讯作者：
Coon, John
中科院分区：
文献类型：
--
作者：
Bonomi, Philip D.;Buckingham, Lela;Coon, John
在非小细胞肺癌（NSCLC）患者中识别表皮生长因子受体酪氨酸激酶（EGFR TKI）的客观肿瘤消退导致了全球范围内的密集临床和基础研究，旨在寻找EGFR TKI在NSCLC中的最佳用途。EGFR TKI临床试验表明，较高的缓解率和较长的生存期与特定的患者特征相关，在EGFR TKI治疗的同时使用常规化疗不会增加生存期。分子研究表明，EGFR激活突变和高EGFR基因拷贝数常见于EGFR TKI治疗结局最佳的患者。最近的研究表明，KRAS突变可以识别EGFR TKI治疗结局最差的患者亚组。目前，研究人员正在试图确定选择EGFR TKI治疗患者的最佳方法。在本综述中讨论了评价EGFR TKI治疗NSCLC患者临床特征和/或分子特征潜在预测价值的研究。
Identification of objective tumor regressions with epidermal growth factor receptor tyrosine kinases (EGFR TKI) in non -small cell lung cancer (NSCLC) patients has resulted in intense, worldwide clinical and basic research directed toward finding the optimal use of EGFR TKIs in NSCLC. EGFR TKI clinical trials have shown that higher response rates and longer survival are associated with specific patient characteristics and that using conventional chemotherapy simultaneously with EGFR TKIs in unselected patients does not increase survival. Molecular studies have revealed that EGFR-activating mutations and high EGFR gene copy number are frequently found in patients who have the best outcomes with EGFR TKIs. More recent studies suggest that KRAS mutations may identify the subset of patients who have the worst outcome with the EGFR TKI treatment. Currently, investigators are trying to determine the optimal approach to selecting patients for treatment with EGFR TKIs. Studies that have evaluated the potential predictive value of clinical features and/or molecular profiles in EGFR TKI-treated NSCLC patients are discussed in this review.